BRPI0716554A2 - compostos de mÉtodos para agentes rotulados de 18f - Google Patents

compostos de mÉtodos para agentes rotulados de 18f

Info

Publication number
BRPI0716554A2
BRPI0716554A2 BRPI0716554-4A2A BRPI0716554A BRPI0716554A2 BR PI0716554 A2 BRPI0716554 A2 BR PI0716554A2 BR PI0716554 A BRPI0716554 A BR PI0716554A BR PI0716554 A2 BRPI0716554 A2 BR PI0716554A2
Authority
BR
Brazil
Prior art keywords
labeled agents
compound methods
compound
methods
labeled
Prior art date
Application number
BRPI0716554-4A2A
Other languages
English (en)
Portuguese (pt)
Inventor
Lutz Lehmann
Ananth Srinivasan
Thomas Brumby
Timo Stellfeld
Keith Graham
Mylene Karramkam
Detlev Suelzle
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP06090166A external-priority patent/EP1897885A1/en
Priority claimed from EP07090079A external-priority patent/EP1985624A3/en
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of BRPI0716554A2 publication Critical patent/BRPI0716554A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C07K14/6555—Somatostatins at least 1 amino acid in D-form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0716554-4A2A 2006-09-08 2007-09-07 compostos de mÉtodos para agentes rotulados de 18f BRPI0716554A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06090166A EP1897885A1 (en) 2006-09-08 2006-09-08 Compounds and methods for F labelled agents
EP07090079A EP1985624A3 (en) 2007-04-23 2007-04-23 Single step method of radiofluorination of biologically active compounds or biomolecules
PCT/EP2007/008042 WO2008028688A2 (en) 2006-09-08 2007-09-07 Compounds and methods for 18f labeled agents

Publications (1)

Publication Number Publication Date
BRPI0716554A2 true BRPI0716554A2 (pt) 2013-09-24

Family

ID=39031005

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0716554-4A2A BRPI0716554A2 (pt) 2006-09-08 2007-09-07 compostos de mÉtodos para agentes rotulados de 18f

Country Status (20)

Country Link
US (1) US8557776B2 (enExample)
EP (5) EP2289564A3 (enExample)
JP (2) JP5603074B2 (enExample)
KR (1) KR20090058553A (enExample)
AR (1) AR062726A1 (enExample)
AU (1) AU2007294124A1 (enExample)
BR (1) BRPI0716554A2 (enExample)
CA (2) CA2662449A1 (enExample)
CL (1) CL2007002620A1 (enExample)
CO (1) CO6150196A2 (enExample)
CR (1) CR10654A (enExample)
IL (4) IL197363A0 (enExample)
MA (1) MA30780B1 (enExample)
MX (1) MX2009002492A (enExample)
NO (1) NO20091428L (enExample)
PE (1) PE20080850A1 (enExample)
RU (1) RU2009112716A (enExample)
TN (1) TN2009000063A1 (enExample)
TW (1) TW200829277A (enExample)
WO (1) WO2008028688A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2662449A1 (en) 2006-09-08 2008-03-13 Bayer Schering Pharma Aktiengesellschaft Compounds and methods for 18f labeled agents
EA200901142A1 (ru) * 2007-03-01 2010-04-30 Байер Шеринг Фарма Акциенгезельшафт 18f фторбензоильные меченые биологически активные соединения в качестве диагностических визуализирующих средств, а также бензотриазол-1-илоксибензоильные, 2,5-(диоксопирролидин-1-илокси)бензоильные и триметиламмониобензоильные предшественники
GB201013808D0 (en) 2010-08-18 2010-09-29 Ge Healthcare Ltd Peptide radiotracer compositions
WO2012094334A1 (en) * 2011-01-04 2012-07-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services One-step 18f labeling of biological substrates and uses of 18f labeled biological substrates
WO2012170602A1 (en) * 2011-06-09 2012-12-13 Ge Healthcare Limited Distillation device and method
HUE061402T2 (hu) * 2013-03-15 2023-06-28 Cancer Targeted Tech Llc 18F-jelölt PSMA-célzott PET képalkotó ágensek elõállításának módszerei és diagnosztikai módszerek velük
GB201314936D0 (en) 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
GB201322456D0 (en) 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
US11518754B2 (en) 2017-02-17 2022-12-06 Yale University Radiolabeled pharmaceuticals and methods of making and using same
AU2018300069C1 (en) 2017-07-11 2025-11-20 Synthorx, Inc. Incorporation of unnatural nucleotides and methods thereof
MX2020001332A (es) 2017-08-03 2020-09-09 Synthorx Inc Conjugados de citoquina para el tratamiento de enfermedades proliferativas e infecciosas.
JP2021522196A (ja) * 2018-04-20 2021-08-30 ザ ジェネラル ホスピタル コーポレイション 血液脳関門を越えて送達するためのアセチル化プロドラッグ
BR112021014415A2 (pt) 2019-02-06 2021-09-21 Synthorx, Inc. Conjugados de il-2 e métodos de uso dos mesmos
CN113150065B (zh) * 2021-03-11 2022-07-08 武汉英纳氏药业有限公司 一种合成肽及其应用
WO2022246118A2 (en) * 2021-05-20 2022-11-24 The Regents Of The University Of California Pet imaging tracers
WO2024204842A1 (ja) 2023-03-31 2024-10-03 日産化学株式会社 ピラゾール化合物及び有害生物防除剤

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989002897A1 (en) * 1987-09-24 1989-04-06 The Administrators Of The Tulane Educational Fund Therapeutic peptides
US5723578A (en) * 1987-09-24 1998-03-03 The Administrators Of Tulane Educational Fund Peptide analogs of bombesin
US5084555A (en) 1989-08-21 1992-01-28 The Administrators Of The Tulane Educational Fund An octapeptide bombesin analog
DE68928667T2 (de) * 1988-10-14 1998-10-01 Univ Tulane Peptide als arzneimittel
JP2846463B2 (ja) * 1989-06-02 1999-01-13 ジョージタウン・ユニバーシティー 抗ストレプトキナーゼ抗体の検出方法
US6232071B1 (en) 1990-06-11 2001-05-15 Gilead Sciences, Inc. Tenascin-C nucleic acid ligands
US5244883A (en) 1990-11-29 1993-09-14 The Administrators Of The Tulane Educational Fund Nonapeptide bombesin antagonists
TW432073B (en) 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
AU2010299A (en) 1997-12-24 1999-07-19 Vertex Pharmaceuticals Incorporated Prodrugs os aspartyl protease inhibitors
CN1110492C (zh) 1997-12-24 2003-06-04 沃泰克斯药物股份有限公司 天冬氨酰蛋白酶抑制剂的前药
WO1999033795A1 (en) 1997-12-24 1999-07-08 Vertex Pharmaceuticals Incorporated Prodrugs of aspartyl protease inhibitors
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
US6639076B1 (en) 1998-08-18 2003-10-28 Eli Lilly And Company Growth hormone secretagogues
ATE303988T1 (de) 1999-06-14 2005-09-15 Lilly Co Eli Inhibitoren von serin proteasen
US7115766B2 (en) 2000-11-30 2006-10-03 Indiana University Research & Technology Corp. Nucleophilic approach for preparing radiolabeled imaging agents and associated compounds
GB0115927D0 (en) * 2001-06-29 2001-08-22 Nycomed Amersham Plc Solid-phase nucleophilic fluorination
GB0206750D0 (en) 2002-03-22 2002-05-01 Amersham Plc Radiofluorination methods
EP1497316B1 (en) * 2002-04-09 2006-07-05 Eli Lilly And Company Growth hormone secretagogues
CA2493471C (en) * 2002-08-09 2013-02-12 Yamanouchi Europe B.V. Compounds binding to p-selectin
US20080063599A1 (en) 2002-11-18 2008-03-13 Jorge Setoain Quinquer Compounds Which Can Be Used To Diagnose And Monitor Diseases Associated With The Formation Of Amyloid Protein Fibrils
CA2516685A1 (en) * 2003-02-20 2004-09-02 University Of South Florida Peptidomimetic inhibitors of stat3 activity and their medical uses
GB0305704D0 (en) 2003-03-13 2003-04-16 Amersham Plc Radiofluorination methods
WO2006083424A2 (en) 2004-12-28 2006-08-10 The Trustees Of Columbia University In The City Of New York Radiolabeled compounds and uses thereof
US20100016295A1 (en) 2005-07-29 2010-01-21 Bayer Healthcare Llc Preparation and Use of Biphenyl Amino Acid Derivatives for the Treatment of Obesity
US20080029548A1 (en) 2006-05-05 2008-02-07 Ann De Wree Fabric treatment dispensing package
CA2662449A1 (en) 2006-09-08 2008-03-13 Bayer Schering Pharma Aktiengesellschaft Compounds and methods for 18f labeled agents

Also Published As

Publication number Publication date
CR10654A (es) 2009-04-14
EP2455105B1 (en) 2016-02-17
EP2455105A2 (en) 2012-05-23
CO6150196A2 (es) 2010-04-20
EP2063918A2 (en) 2009-06-03
JP5722966B2 (ja) 2015-05-27
TN2009000063A1 (en) 2010-08-19
EP2289564A3 (en) 2012-11-14
TW200829277A (en) 2008-07-16
NO20091428L (no) 2009-06-03
IL211526A0 (en) 2011-05-31
EP2289564A2 (en) 2011-03-02
WO2008028688A2 (en) 2008-03-13
JP5603074B2 (ja) 2014-10-08
EP2455105A3 (en) 2012-09-05
CL2007002620A1 (es) 2008-05-30
WO2008028688A3 (en) 2008-11-13
CA2662449A1 (en) 2008-03-13
EP3056509A1 (en) 2016-08-17
JP2010503618A (ja) 2010-02-04
IL211527A0 (en) 2011-05-31
JP2014028813A (ja) 2014-02-13
IL197363A0 (en) 2011-08-01
EP2279759A2 (en) 2011-02-02
EP2279759A3 (en) 2013-04-17
AU2007294124A1 (en) 2008-03-13
MX2009002492A (es) 2009-08-28
US8557776B2 (en) 2013-10-15
RU2009112716A (ru) 2010-10-20
IL211033A0 (en) 2011-04-28
EP2063918B1 (en) 2014-02-26
CA2858907A1 (en) 2008-03-13
MA30780B1 (fr) 2009-10-01
AR062726A1 (es) 2008-11-26
PE20080850A1 (es) 2008-09-02
KR20090058553A (ko) 2009-06-09
US20080292548A1 (en) 2008-11-27

Similar Documents

Publication Publication Date Title
BRPI0716554A2 (pt) compostos de mÉtodos para agentes rotulados de 18f
LTPA2020501I1 (lt) Pakeistieji enaminokarbonilo junginiai
ATE443753T1 (de) Nuancierungsmittel
EP1985620A4 (en) COMPOUND 10a-AZALIDE
CR10705A (es) Anticuerpos para linfotoxina-alfa
ATE524477T1 (de) Aziridinylepothilonverbindungen
PL2067108T3 (pl) Lokalizowanie węzłów odniesienia do pozycjonowania
DK2086939T3 (da) Pyridiacarboxamid som II-beta-HSDI-inhibitorer
DE602007008787D1 (de) Spannvorrichtung
BRPI0814706A2 (pt) Meios para remoção de compostos orgânicos
DE112007001674A5 (de) Spannvorrichtung
NO2015006I1 (no) Flutemetamol (18F)
DE112007003149A5 (de) Spannfutter
DE502006004094D1 (de) Bohrfutter
DE112007000530A5 (de) Kopfplatte
ZA200902422B (en) Compounds and methods for 18F labeled agents
BRPI0820430A2 (pt) Composto
DE112007000971A5 (de) Spannvorrichtung
SE0601103L (sv) Redskapsbärare
ES1063735Y (es) Testero para persiana
ES1065835Y (es) Caperuza para cetreria
ES1065168Y (es) Soporte para biberon
ES1063779Y (es) Pallon para gaitas
ES1063389Y (es) Embalaje-expositor para tuberias
ES1064561Y (es) Electrovalvula para grifo

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 5A, 6A E 7A ANUIDADES.

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2277 DE 26/08/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A, 7A, 8A, 9A, 10A, 11A, 12A E 13A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.